EMPEROR-Reduced

The EMPEROR-Reduced trial evaluated the efficacy and safety of empagliflozin in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were receiving standard of care treatment. This module details the design and results of the trial.

EMPEROR-Reduced
Rate this content
  • EMPEROR-Reduced
  • EMPEROR-Reduced
  • EMPEROR-Reduced
  • EMPEROR-Reduced: trial design
  • EMPEROR-Reduced: key inclusion and exclusion criteria
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go